USA Market
eCTD Publishing Services
Drug
ENQUIRE NOW
What Is eCTD Publishing Services?
eCTD stands for Electronic Common Technical Document. It's the FDA's required format for submitting drug-related applications electronically. Whether you're filing a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or a commercial Investigational New Drug (IND), eCTD is the standard format the FDA accepts.
CliniExperts helps pharma companies navigate this process with ease. We take your regulatory documents and transform them into fully compliant, technically validated eCTD sequences, ready for submission through the FDA's secure Electronic Submission Gateway (ESG).
Why Is eCTD Publishing Services Important?
FDA Compliance
FDA doesn’t accept paper submissions or outdated formats anymore. If your submission isn’t in eCTD format, it will be rejected.
Faster Reviews
The eCTD’s digital structure supports faster reviews by providing clear, structured data.
Lifecycle Management
It simplifies lifecycle management—you can easily update, amend, or supplement your original applications.
Data Integrity
It protects data integrity and facilitates secure electronic delivery to the FDA.
Process Flow for eCTD Publishing Services
Initial Review
We start by understanding your submission type—NDA, ANDA, IND, DMF—and assess your timelines and document readiness.
Document Preparation
We format all your documents (PDFs, forms, technical files) according to FDA eCTD standards, adding bookmarks, hyperlinks, and metadata.
Publishing & Validation
We compile your application using advanced publishing software. Each sequence is validated through both automated tools and manual quality checks.
Submission to FDA
We submit your application directly through the FDA’s ESG system. We also help you get pre-assigned application numbers if needed.
Post-Submission Support
Need to update your submission? No problem. We handle amendments, supplements, annual reports, and more.
How Can We Help in eCTD Publishing Services?
End-to-End Support: From initial document formatting to ESG submission—we cover it all.
Fast Turnaround: Our streamlined workflows deliver eCTDs in days, not weeks.
Confidentiality First: We treat your data with the highest level of security and discretion.
FDA Expertise: Our team knows the ins and outs of Module 1 (regional), Module 2 summaries, and the technical structure of Modules 3, 4, and 5.
Services
| Service | Details |
|---|---|
| New Drug Applications (NDAs) |
|
| Abbreviated New Drug |
|
| Commercial |
|
| Master Files (DMFs) |
|
| Amendments |
|
| Non-commercial INDs |
|
| Promotional Material Submissions |
|
Regulatory Requirements for eCTD Publishing Services
Documents
eCTD submissions are structured according to the Common Technical Document (CTD) format defined by the International Council for Harmonisation (ICH), and must include:
- Module 1 – Region-specific information (cover letters, forms like FDA 356h, application numbers, etc.)
- Module 2 – CTD summaries (quality overall summary, nonclinical and clinical overview)
- Module 3 – Quality information (CMC data)
- Module 4 – Nonclinical study reports
- Module 5 – Clinical study reports
Additional documents:
- Validation reports to ensure submission structure compliance.
- Metadata XML files and leaf files that guide reviewers.
All documents must follow strict formatting guidelines including:
- PDF v1.4–1.7
- Bookmarks, hyperlinks, fonts, naming conventions
Timeline
Timelines can vary depending on the type and complexity of the submission:
- New Applications (NDA, ANDA, IND): Typically 5–10 business days after all documents are received and finalized.
- Amendments, Supplements, Reports: Usually processed within 2–4 business days.
- DMF Submissions: 5–7 business days.
- Promotional Submissions: Typically 2–3 days.
Expedited processing may be available upon request, subject to additional costs or prioritization arrangements.
Regulatory Body
The U.S. Food and Drug Administration (FDA) is the primary authority responsible for reviewing and accepting eCTD submissions.
Specifically:
- Submissions for human drugs are managed by the Center for Drug Evaluation and Research (CDER).
- For biologics, the relevant center is the Center for Biologics Evaluation and Research (CBER).
- All submissions must go through the Electronic Submission Gateway (ESG)—the FDA’s secure portal for receiving electronic regulatory files.
Fees
Regulatory Authority Fees: FDA itself does not charge a separate fee for the act of submitting an eCTD. However, application review fees (e.g., PDUFA fees) may still apply, which are independent of publishing service costs.
Service Provider Fees: Vary widely depending on:
- Number of documents/modules
- Level of formatting and QC required
- Submission type (original, variation, annual report, etc.)
Validity
Each eCTD sequence remains valid as part of the submission’s lifecycle.
The lifecycle management (amendments, supplements, annual reports) must be maintained in eCTD format once initiated.
Frequently Asked Questions(FAQs)
Is eCTD mandatory for all submissions?
Yes. If you’re manufacturing, repackaging, or relabeling drugs for commercial use in the U.S., you must register and list.
How often do I need to update the listing?
At least twice a year (June and December), or immediately if your product information changes.
Can you convert my current label to SPL format?
Absolutely—we’ll handle all SPL conversions, validation, and formatting for you.
What if I’ve never submitted to the FDA before?
No worries. We guide you through FEI registration, labeler code setup, and first-time drug listing.
Do you serve non-U.S. companies?
Yes! We work with global pharma companies entering or distributing in the U.S. market.
